Scientists studied nine single nucleotide polymorphisms which influence LDL levels. From homozygous familial hypercholesterolemia at the high extreme (over 600 mg/dL LDL cholesterol) to hypobeta-lipoproteinemia at the low extreme (less than 15mg/dL LDL cholesterol). Since these SNP's are present from birth, this allowed them to see the effect of low LDL levels maintained over a lifetime. The results show a three times greater benefit for these life long low LDL levels compared taking statins later in life. Ference stated, "the effect of each of the included SNPs on risk of CHD is mediated largely or entirely through effect on circulating levels of LDL, rather than through some other pleiotropic effect."
"The researchers also conducted a meta-analysis of the "natural" randomized trials by combining non-overlapping data from multiple SNPs involving 326,443 participants. Results of this study indicated that lifetime exposure to lower LDL was associated with a 54% (95% CI, 48-59) relative reduction of CVD for each 38.7 mg/dL (1 mmol/L) lower LDL." There is a clear dose response relationship. And no one is suggesting that people that statins all their life, but low animal fat diets can do a lot to improve LDL.
Ference BA. Late-breaking clinical trials IV. Presented at: the American College of Cardiology 61st Scientific Session & Expo; March 24-27, 2012; Chicago
http://www.endocrinetoday.com/view.aspx?rid=95991
Modified 04-20-2012
